Trials / Recruiting
RecruitingNCT06737731
A Phase I/II Clinical Study of SHR-1681 for Injection in Patients With Advanced Solid Tumors
A Phase I/II, Multicenter, Open-Label Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-1681 for Injection in Patients With Malignant Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 300 (estimated)
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is an open-label, multicenter Phase I/II clinical trial to evaluate the safety, tolerability, pharmacokinetics and efficacy of SHR-1681 for injection in patients with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-1681 | SHR-1681 for Injection will be administrated per dose level in which the patients are assigned. |
Timeline
- Start date
- 2025-01-21
- Primary completion
- 2026-11-01
- Completion
- 2027-07-01
- First posted
- 2024-12-17
- Last updated
- 2026-01-09
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06737731. Inclusion in this directory is not an endorsement.